GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » EV-to-EBIT

China National Accord Medicines (SZSE:000028) EV-to-EBIT : 7.71 (As of May. 21, 2024)


View and export this data going back to 1993. Start your Free Trial

What is China National Accord Medicines EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, China National Accord Medicines's Enterprise Value is ¥20,725 Mil. China National Accord Medicines's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥2,689 Mil. Therefore, China National Accord Medicines's EV-to-EBIT for today is 7.71.

The historical rank and industry rank for China National Accord Medicines's EV-to-EBIT or its related term are showing as below:

SZSE:000028' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.97   Med: 10.36   Max: 32.61
Current: 7.71

During the past 13 years, the highest EV-to-EBIT of China National Accord Medicines was 32.61. The lowest was 5.97. And the median was 10.36.

SZSE:000028's EV-to-EBIT is ranked better than
71.6% of 81 companies
in the Medical Distribution industry
Industry Median: 12.94 vs SZSE:000028: 7.71

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. China National Accord Medicines's Enterprise Value for the quarter that ended in Mar. 2024 was ¥21,499 Mil. China National Accord Medicines's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥2,689 Mil. China National Accord Medicines's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 12.51%.


China National Accord Medicines EV-to-EBIT Historical Data

The historical data trend for China National Accord Medicines's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines EV-to-EBIT Chart

China National Accord Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.76 8.38 7.97 5.79 6.72

China National Accord Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.98 10.15 8.09 6.72 7.99

Competitive Comparison of China National Accord Medicines's EV-to-EBIT

For the Medical Distribution subindustry, China National Accord Medicines's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China National Accord Medicines's EV-to-EBIT Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where China National Accord Medicines's EV-to-EBIT falls into.



China National Accord Medicines EV-to-EBIT Calculation

China National Accord Medicines's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=20724.850/2689.142
=7.71

China National Accord Medicines's current Enterprise Value is ¥20,725 Mil.
China National Accord Medicines's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,689 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China National Accord Medicines  (SZSE:000028) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

China National Accord Medicines's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=2689.142/21499.1378
=12.51 %

China National Accord Medicines's Enterprise Value for the quarter that ended in Mar. 2024 was ¥21,499 Mil.
China National Accord Medicines's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,689 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China National Accord Medicines EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


China National Accord Medicines (SZSE:000028) Business Description

Traded in Other Exchanges
Address
No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.

China National Accord Medicines (SZSE:000028) Headlines

No Headlines